NCT03138928

Brief Summary

Purpose: To report the follow-up data for patients who had XEN45 gel stent implantation, a new method of minimally invasive glaucoma surgery (MIGS). Material and Methods: Fifteen eyes of fifteen patients who had XEN45 gel stent implantation surgery were investigated in the study. All the patients were examined preoperatively and at the following postoperative time points: 1 day; 1 and 2 weeks; and 1, 2, 3, 6, and 12 months. Intraocular pressure (IOP) was measured by Goldmann applanation tonometry. Combined surgical procedures (XEN 45 + phacoemulsification + intraocular lens) were performed in the cases that had cataracts in addition to glaucoma.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2015

Typical duration for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2016

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2017

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 25, 2017

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 3, 2017

Completed
Last Updated

May 8, 2017

Status Verified

May 1, 2017

Enrollment Period

1.2 years

First QC Date

April 25, 2017

Last Update Submit

May 3, 2017

Conditions

Keywords

glaucomatrabeculectomyminimally invasive glaucoma surgeryXEN45 gel stent

Outcome Measures

Primary Outcomes (1)

  • Intraocular pressure

    Mean intraocular pressure values

    Postoperative 12 months

Secondary Outcomes (2)

  • Antiglaucomatous medications

    Postoperative 12 months

  • Incidence of complications

    Postoperative 12 months

Interventions

The XEN gel stent (Allergan, Dublin, Ireland) is a recently developed, permanent, ab interno collagen implant that reduces IOP by draining aqueous fluid from the anterior chamber into the subconjunctival space

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Fifteen patients who had an XEN45 gel stent implantation surgery between January 2015 and March 2016 were enrolled in the study.

You may qualify if:

  • Primary open-angle glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma, with uncontrolled IOP and progressive visual field damage despite using the maximum tolerated dose of topical antiglaucomatous medications. Patients who had previous glaucoma surgery were included as well.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (17)

  • Sheybani A, Lenzhofer M, Hohensinn M, Reitsamer H, Ahmed II. Phacoemulsification combined with a new ab interno gel stent to treat open-angle glaucoma: Pilot study. J Cataract Refract Surg. 2015 Sep;41(9):1905-9. doi: 10.1016/j.jcrs.2015.01.019. Epub 2015 Oct 23.

    PMID: 26482822BACKGROUND
  • Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014 Nov;121(11):2081-90. doi: 10.1016/j.ophtha.2014.05.013. Epub 2014 Jun 26.

  • Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002 Oct;120(10):1268-79. doi: 10.1001/archopht.120.10.1268.

  • Nouri-Mahdavi K, Brigatti L, Weitzman M, Caprioli J. Outcomes of trabeculectomy for primary open-angle glaucoma. Ophthalmology. 1995 Dec;102(12):1760-9. doi: 10.1016/s0161-6420(95)30796-8.

  • Landers J, Martin K, Sarkies N, Bourne R, Watson P. A twenty-year follow-up study of trabeculectomy: risk factors and outcomes. Ophthalmology. 2012 Apr;119(4):694-702. doi: 10.1016/j.ophtha.2011.09.043. Epub 2011 Dec 23.

  • Minckler D, Mosaed S, Dustin L, Ms BF; Trabectome Study Group. Trabectome (trabeculectomy-internal approach): additional experience and extended follow-up. Trans Am Ophthalmol Soc. 2008;106:149-59; discussion 159-60.

  • Ting JL, Damji KF, Stiles MC; Trabectome Study Group. Ab interno trabeculectomy: outcomes in exfoliation versus primary open-angle glaucoma. J Cataract Refract Surg. 2012 Feb;38(2):315-23. doi: 10.1016/j.jcrs.2011.08.043.

  • Bussel II, Kaplowitz K, Schuman JS, Loewen NA; Trabectome Study Group. Outcomes of ab interno trabeculectomy with the trabectome by degree of angle opening. Br J Ophthalmol. 2015 Jul;99(7):914-9. doi: 10.1136/bjophthalmol-2014-305577. Epub 2014 Oct 21.

  • Lewis RA. Ab interno approach to the subconjunctival space using a collagen glaucoma stent. J Cataract Refract Surg. 2014 Aug;40(8):1301-6. doi: 10.1016/j.jcrs.2014.01.032. Epub 2014 Jun 15.

  • Vera V, Horvath C. Xen Gel Stent: The solution designed by AqueSys. In: Samples, JR, Ahmed, IIK, editors. Surgical innovations in glaucoma. New York: Springer Science+Business Media; 2014, p. 189-198.

    RESULT
  • Richter GM, Coleman AL. Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol. 2016 Jan 28;10:189-206. doi: 10.2147/OPTH.S80490. eCollection 2016.

  • Kerr NM, Wang J, Barton K. Minimally invasive glaucoma surgery as primary stand-alone surgery for glaucoma. Clin Exp Ophthalmol. 2017 May;45(4):393-400. doi: 10.1111/ceo.12888. Epub 2017 Jan 29.

  • Garcia-Feijoo J, Sampaolesi JR. A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma. Clin Ophthalmol. 2012;6:441-6. doi: 10.2147/OPTH.S29158. Epub 2012 Mar 22.

  • Valente C, Iester M, Corsi E, Rolando M. Symptoms and signs of tear film dysfunction in glaucomatous patients. J Ocul Pharmacol Ther. 2011 Jun;27(3):281-5. doi: 10.1089/jop.2010.0133. Epub 2011 May 10.

  • Dupont G, Collignon N. [NEW SURGICAL APPROACH IN PRIMARY OPEN-ANGLE GLAUCOMA: XEN GEL STENT A MINIMALLY INVASIVE TECHNIQUE]. Rev Med Liege. 2016 Feb;71(2):90-3. French.

  • Perez-Torregrosa VT, Olate-Perez A, Cerda-Ibanez M, Gargallo-Benedicto A, Osorio-Alayo V, Barreiro-Rego A, Duch-Samper A. Combined phacoemulsification and XEN45 surgery from a temporal approach and 2 incisions. Arch Soc Esp Oftalmol. 2016 Sep;91(9):415-21. doi: 10.1016/j.oftal.2016.02.006. Epub 2016 Mar 16. English, Spanish.

  • Pinto Ferreira N, Abegao Pinto L, Marques-Neves C. XEN Gel Stent Internal Ostium Occlusion: Ab-Interno Revision. J Glaucoma. 2017 Apr;26(4):e150-e152. doi: 10.1097/IJG.0000000000000625.

MeSH Terms

Conditions

Glaucoma

Condition Hierarchy (Ancestors)

Ocular HypertensionEye Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ass. Proff, M.D.

Study Record Dates

First Submitted

April 25, 2017

First Posted

May 3, 2017

Study Start

January 1, 2015

Primary Completion

March 1, 2016

Study Completion

March 1, 2017

Last Updated

May 8, 2017

Record last verified: 2017-05

Data Sharing

IPD Sharing
Will share

This clinical trial is under review for publishing. If it is accepted for publishing,our results will be shared.